Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | DUT | P33316 | 5/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575501 | 0.90 | P2RY2 (0.54) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL31467672 | 0.90 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL21905172 | 0.90 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL19185368 | 0.88 | CYP3A4 (0.52) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL31657606 | 0.88 | CYP3A4 (0.52) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL12701331 | 0.88 | TYMP (0.45) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL17737292 | 0.88 | CYP3A4 (0.52) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL31657584 | 0.88 | CYP3A4 (0.52) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL4292414 | 0.87 | TYMP (0.43) | TYMPP2RY2P2RY4CYP3A4CYP2C9 | |
| SCHEMBL15602744 | 0.86 | TYMP (0.40) | TYMPP2RY2P2RY4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269839-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3296306-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2022-11-09 | — | — | EP | disclosed |
| US-20200140476-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| EP-2711370-B1 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | AJINOMOTO KK (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9029528-B2 | Solution-based method of making oligonucleotides via phosphoramidite coupling | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | PNP, PCNA, NUDT14 | TYMP 4/4885P2RY2 1046/4885P2RY4 590/4885 |
| US-12269839-B2 | Chiral phosphoramidite auxiliaries and methods of their use | PNP, PCNA, NUDT14 | TYMP 4/4885P2RY2 1046/4885P2RY4 590/4885 |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | TYMP, PNP, PCNA | TYMP 1/4885P2RY2 695/4885P2RY4 469/4885 |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | TYMP 66/4885P2RY2 1974/4885P2RY4 717/4885 |
| US-20200140476-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | PNP, PCNA, NUDT14 | TYMP 4/4885P2RY2 1046/4885P2RY4 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.